Literature DB >> 20926939

The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review.

Christos G Mihos1, Maria J Salas, Orlando Santana.   

Abstract

The hydroxy-methyl-glutaryl-CoA reductase inhibitors (statins) are used extensively in the treatment of hyperlipidemia, and in the long-term prevention of coronary artery disease and stroke. They have also demonstrated a benefit in a variety of other cardiovascular disease processes. These secondary actions are known as pleiotropic effects. An updated discussion on the pleiotropy of statins is provided, and emphasizes the importance of randomized, placebo-controlled trials to further elucidate the potential benefits of these non-lipid-lowering actions in the treatment of cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20926939     DOI: 10.1097/CRD.0b013e3181f52a7f

Source DB:  PubMed          Journal:  Cardiol Rev        ISSN: 1061-5377            Impact factor:   2.644


  26 in total

1.  Author reply to comment on "atorvastatin safety in Kawasaki disease patients with coronary artery aneurysms".

Authors:  Cedric Manlhiot; Brian W McCrindle
Journal:  Pediatr Cardiol       Date:  2013-10-15       Impact factor: 1.655

2.  Poor outcomes despite aspirin or statin use in high-risk patients with retinal vein occlusion.

Authors:  Vlad M Matei; Jonathan Y Xia; Chan Nguyen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-12-21       Impact factor: 3.117

Review 3.  Predictors of statin adherence.

Authors:  Alexander Mauskop; William B Borden
Journal:  Curr Cardiol Rep       Date:  2011-12       Impact factor: 2.931

4.  Phase I/IIa Trial of Atorvastatin in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysm.

Authors:  Adriana H Tremoulet; Sonia Jain; Pei-Ni Jone; Brookie M Best; Elizabeth H Duxbury; Alessandra Franco; Beth Printz; Samuel R Dominguez; Heather Heizer; Marsha S Anderson; Mary P Glodé; Feng He; Robert L Padilla; Chisato Shimizu; Emelia Bainto; Joan Pancheri; Harvey J Cohen; John C Whitin; Jane C Burns
Journal:  J Pediatr       Date:  2019-09-24       Impact factor: 4.406

5.  Teaching an old dog new tricks: potential antiatherothrombotic use for statins.

Authors:  Roy L Silverstein
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

Review 6.  Impact of statin therapy on plasma leptin concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials.

Authors:  Amirhossein Sahebkar; Renato Giua; Claudio Pedone
Journal:  Br J Clin Pharmacol       Date:  2016-10-04       Impact factor: 4.335

Review 7.  Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.

Authors:  Behzad Yeganeh; Emilia Wiechec; Sudharsana R Ande; Pawan Sharma; Adel Rezaei Moghadam; Martin Post; Darren H Freed; Mohammad Hashemi; Shahla Shojaei; Amir A Zeki; Saeid Ghavami
Journal:  Pharmacol Ther       Date:  2014-02-26       Impact factor: 12.310

8.  Evaluating a novel treatment for coronary artery inflammation in acute Kawasaki disease: A Phase I/IIa trial of atorvastatin.

Authors:  Adriana H Tremoulet; Sonia Jain; Jane C Burns
Journal:  Expert Opin Orphan Drugs       Date:  2015-07-13       Impact factor: 0.694

9.  Simvastatin abrogates inflamed neutrophil adhesive properties, in association with the inhibition of Mac-1 integrin expression and modulation of Rho kinase activity.

Authors:  Angélica Aparecida Antoniellis Silveira; Venina Marcela Dominical; Mariana Lazarini; Fernando Ferreira Costa; Nicola Conran
Journal:  Inflamm Res       Date:  2012-12-19       Impact factor: 4.575

10.  Atorvastatin safety in Kawasaki disease patients with coronary artery aneurysms.

Authors:  Elizabeth Niedra; Nita Chahal; Cedric Manlhiot; Rae S M Yeung; Brian W McCrindle
Journal:  Pediatr Cardiol       Date:  2013-07-18       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.